Betaxolol detailed information

Betaxolol detailed information

Clinical data
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	oral, ocular
ATC code	C07AB05 (WHO) S01ED02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	89%
Metabolism	Hepatic
Elimination half-life	14-22hours
Excretion	Renal (20%)
Identifiers
IUPAC name 1-[4-[2-(cyclopropylmethoxy) ethyl]phenoxy]-3- (1-methylethylamino)propan-2-ol
CAS Number	63659-18-7
PubChem CID	2369
DrugBank	APRD00245
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H29NO3
Molar mass	307.428 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Betaxolol (trade names Betoptic, Betoptic S, Lokren) is a selective beta₁ receptor blocker used in the treatment of hypertension and glaucoma. Being selective for beta₁ receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm (mediated by beta₂ receptors) as timolol may. Betaxolol also shows greater affininty for beta₁ receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye (intraocular pressure). This effect is thought to be caused by reducing the production of the liquid (which is called the aqueous humor) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

Betaxolol was approved by the U.S. Food and Drug Administration (FDA) for ocular use as a 0.5% solution (Betoptic) in 1985 and as a 0.25% solution (Betoptic S) in 1989.

See also

Levobetaxolol